FOLLOW US

Type 2 Diabetes Research Updates

For Medical Professionals

Researchers have developed a diabetes algorithm to supplement clinical decision-making when establishing glycemic goals for patients with type 2 diabetes, according to a study reported in the December issue of Diabetes Care.
The U.S. Food and Drug Administration (FDA) announced that it has eliminated the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines (ie, Avandia, Avandamet, Avandaryl, and generics).
Predictors of diabetes remission varied by type of bariatric surgery, according to a study published online ahead of print in Diabetes Care. The relationship between bariatric surgery and diabetes remission appears to be independent of baseline BMI, the study authors reported.
It is unclear whether antibiotics are directly linked to type 2 diabetes or if patients requiring repeated antibiotic use have undiagnosed diabetes, placing them at increased risk of infections.
Adults ages 40 to 70 years who are overweight or obese and do not have symptoms of diabetes should be screened for abnormal blood glucose levels as part of an overall cardiovascular risk assessment, according to a recommendation statement issued by the U.S. Preventive Services Task Force.
New findings suggest that the GLP-1 receptor agonist liraglutide may prevent osteoporosis when used for chronic weight management in post-menopausal women with type 2 diabetes..
Nonalcoholic fatty liver disease (NAFLD) was found in 50% of patients with type 2 diabetes who had normal aminotransferase levels in a recent study reported in the June issue of the Journal of Clinical Endocrinology & Metabolism.
The t:flex™ Insulin Pump was approved for marketing by the U.S. Food and Drug Administration, making it the largest-capacity insulin pump available in the United States.
Glyxambi is now approved as an adjunct to nutrition and physical activity for the treatment of adults with type 2 diabetes mellitus. Glyxambi, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, is the first diabetes treatment in the United States to combine the dual mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Studies suggest that up to 20% of people with type 2 diabetes may be exercise resistant—meaning that they do not see any improvement in glucose level when following a supervised exercise regimen, according to a systematic review.
According to a prospective cohort study published online ahead of print in The Spine Journal, patients with type 2 diabetes had significant reductions in A1C levels following decompression spine surgery to treat lumbar spinal stenosis.
The U.S. Preventive Services Task Force (USPSTF) has issued a draft recommendation regarding screening for abnormal blood glucose levels in all adults at increased risk for type 2 diabetes.
Dulaglutide (Trulicity), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is now approved as an adjunct to diet and exercise in the treatment of type 2 diabetes in adults.
The U.S. Food and Drug Administration has approved a fixed-dose therapy combining the sodium glucose co-transporter 2 inhibitor canagliflozin and metformin hydrochloride in a single tablet for the treatment of adults with type 2 diabetes.
An estimated 40% of adults in the United States will develop diabetes in their lifetime, with even higher risks found in Hispanic men and women and non-Hispanic black women, according to data from the Centers from Disease Control and Prevention.
The U.S. Food and Drug Administration has approved a third glucagon-like peptide-1 (GLP-1) receptor antagonist—albiglutide—for use as an adjunct to diet and exercise in the treatment of type 2 diabetes.
Many pediatricians and family practice physicians recently surveyed were unaware that hemoglobin A1c is a recommended diagnostic test for type 2 diabetes; however, education on this recommendation was linked an increased number of physicians who said they would use the test in a hypothetical case involving an adolescent, according to a cross-sectional study in the February Journal of Adolescent Health.
Inpatient diabetes education was associated with 34% reduced risk of all-cause readmissions within 30 days, and 20% reduced risk of readmissions at 180 days, after adjustment for other potentially confounding variables, in a retrospective study published in Diabetes Care.
Sulfonylureas are as effective as dipeptidyl peptidase-4 (DDP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists as second-line treatments for type 2 diabetes but at a lower cost, according to a study in February 26 issue of Diabetes Care.
The U.S. Food and Drug Administration (FDA) announced that it will evaluate clinical trial data from the manufacturer of saxagliptin (Onglyza and Kombiglyze XR) to investigate whether this medication is linked to an increased risk of heart failure.
SHOW MAIN MENU
SHOW SUB MENU